Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Beneficial effects of probiotics have been reported in liver disease. Inflammatory bowel disease concurs in 90% of primary sclerosing cholangitis (PSC) patients, suggesting that substances originating from the inflamed gut may damage the biliary tree. OBJECTIVE: To assess potential beneficial effects of probiotics on serum liver tests, pruritus and fatigue in PSC. METHODS: Fourteen patients (13 male/one female, mean age 45 years), with concurrent inflammatory bowel disease were randomized to treatment with probiotics (Ecologic 641, containing four Lactobacillus and two Bifidobacillus strains; Winclove Bio Industries, Amsterdam, The Netherlands) or placebo during 3 months in a double-blind fashion. After a 1-month washout period, crossover was made. RESULTS: No changes in pruritus, fatigue and stool frequency were noted during placebo or probiotics. No significant differences were observed between treatment with probiotics and placebo in bilirubin (at end of probiotic vs. placebo period: -13 vs. -15% change from baseline; P=0.89), alkaline phosphatase (-9 vs. -9%; P=0.99), gamma glutamyl transpeptidase (-11 vs. -5%; P=0.60), aspartate aminotransferase (-16 vs. -15%; P=0.99), alanine aminotransferase (-27 vs. -26%; P=0.97), prothrombin, albumin or bile salts. CONCLUSION: Our data do not support beneficial effects of probiotics on symptoms, liver biochemistry or liver function in PSC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a small study (n = 14) with a probiotic containing Bifidobacillus and Lactobacillus showed no beneficial effects on liver biochemistries, including serum ALP, compared to placebo at the end of treatment over 3 months.212”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [212]
In the citing paper
“Probiotics have been rather disappointing in treatment of NASH60 and cholestatic disorders such as PSC,61”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [61]
Citations
Cites
Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial
Gionchetti, P., Rizzello, F., Helwig, U., Venturi, A., Lammers, K. M., Brigidi, P., Vitali, B., Poggioli, G., Miglioli, M., & Campieri, M. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00171-9 · Cited by 1,147
Rembacken, B., Snelling, A., Hawkey, P., Chalmers, D., & Axon, A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)06343-0 · Cited by 1,101
Li, Z., Yang, S., Lin, H., Huang, J., Watkins, P. A., Moser, A. B., DeSimone, C., Song, X.-Y., & Diehl, A. M. (2003) · Hepatology · doi:10.1053/jhep.2003.50048 · Cited by 930
Liu, Q., Duan, Z. P., Ha, D. K., Bengmark, S., Kurtovic, J., & Riordan, S. M. (2004) · Hepatology · doi:10.1002/hep.20194 · Cited by 638
Ursodiol for Primary Sclerosing Cholangitis
Lindor, K. D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703063361003 · Cited by 598
Pardi, D. S., Loftus, E. V., Kremers, W. K., Keach, J., & Lindor, K. D. (2003) · Gastroenterology · doi:10.1053/gast.2003.50156 · Cited by 562
Alander, M., Satokari, R., Korpela, R., Saxelin, M., Vilpponen-Salmela, T., Mattila-Sandholm, T., & von Wright, A. (1999) · Applied and Environmental Microbiology · doi:10.1128/aem.65.1.351-354.1999 · Cited by 530
Primary Sclerosing Cholangitis
Lee, Y.-M., & Kaplan, M. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321406 · Cited by 526
Beneficial Effects of a Probiotic VSL#3 on Parameters of Liver Dysfunction in Chronic Liver Diseases
Loguercio, C., Federico, A., Tuccillo, C., Terracciano, F., D'Auria, M. V., De Simone, C., & Blanco, C. D. V. (2005) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000165671.25272.0f · Cited by 449
Primary sclerosing cholangitis
Lawson, A. (2014) · Radiopaedia.org · doi:10.53347/rid-26818 · Cited by 443
Cited by
Targeting the gut-liver axis in liver disease
Wiest, R., Albillos, A., Trauner, M., Bajaj, J. S., & Jalan, R. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.007 · Cited by 419
Saez-Lara, M. J., Gomez-Llorente, C., Plaza-Diaz, J., & Gil, A. (2015) · BioMed Research International · doi:10.1155/2015/505878 · Cited by 388
“The absence of any significant positive effects was attributed to the concurrent use of UCDA, the relatively small number of patients studied, or the relatively short duration of treatment [87].”
BackgroundEASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases
Li, Y., Tang, R., Leung, P. S. C., Gershwin, M. E., & Ma, X. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.07.002 · Cited by 247
Effects of dietary components on intestinal permeability in health and disease
Khoshbin, K., & Camilleri, M. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00245.2020 · Cited by 195
Novel therapeutic targets for cholestatic and fatty liver disease
Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204
Ponsioen, C. Y., Chapman, R. W., Chazouillères, O., Hirschfield, G. M., Karlsen, T. H., Lohse, A. W., Pinzani, M., Schrumpf, E., Trauner, M., & Gores, G. J. (2016) · Hepatology · doi:10.1002/hep.28256 · Cited by 179
“27) Silveira MG, Torok NJ, Gossard AA, Keach JC, Jorgensen RA, Petz JL, Lindor KD. Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study.”
BackgroundThe gut microbiota and the liver. Pathophysiological and clinical implications
Quigley, E. M. M., Stanton, C., & Murphy, E. F. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.11.023 · Cited by 133
“Similarly, small studies in compensated cirrhosis [103] and PSC [104] showed no impact from the relatively short-term (3–6 months) administration of probiotic on common laboratory parameters.”
BackgroundThe microbiota and the gut–liver axis in primary sclerosing cholangitis
Hov, J. R., & Karlsen, T. H. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00690-y · Cited by 141
Human Intestinal Barrier: Effects of Stressors, Diet, Prebiotics, and Probiotics
Camilleri, M. (2021) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000308 · Cited by 140
Awoniyi, M., Wang, J., Ngo, B., Meadows, V., Tam, J. W., Viswanathan, A., Lai, Y., Montgomery, S. A., Farmer, M., Kummen, M., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-326500 · Cited by 127
Anti-Inflammatory Diets and Fatigue
Haß, U., Herpich, C., & Norman, K. (2019) · Nutrients · doi:10.3390/nu11102315 · Cited by 136
“Other trials with supplementation of various probiotic mixtures in patients with CFS for 10 weeks [106], colorectal cancer [107] and primary sclerosing cholangitis with IBD for 12 weeks [108], or spondyloarthritis for 4 weeks [109] were not successful in significantly improving the fatigue status.”
BackgroundCholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents
Hasegawa, S., Yoneda, M., Kurita, Y., Nogami, A., Honda, Y., Hosono, K., & Nakajima, A. (2021) · Drugs · doi:10.1007/s40265-021-01545-7 · Cited by 125
“A randomized, placebo-controlled study of probiotics in patients with PSC showed no benefit to PSC symptoms (fatigue, pruritus, or frequency of stools), liver biochemistry, or liver function [101].”
BackgroundProbiotics for patients with hepatic encephalopathy
McGee, R. G., Bakens, A., Wiley, K., Riordan, S. M., & Webster, A. C. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008716.pub2 · Cited by 116
The Gut-Liver Axis in Cholestatic Liver Diseases
Blesl, A., & Stadlbauer, V. (2021) · Nutrients · doi:10.3390/nu13031018 · Cited by 112
Tabibian, J. H., O’Hara, S. P., & Lindor, K. D. (2014) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2014.913189 · Cited by 93
Bahmani, F., Tajadadi-Ebrahimi, M., Kolahdooz, F., Mazouchi, M., Hadaegh, H., Jamal, A.-S., Mazroii, N., Asemi, S., & Asemi, Z. (2016) · Journal of the American College of Nutrition · doi:10.1080/07315724.2015.1032443 · Cited by 92
“In agreement with our study, the consumption of probiotics (Ecologic 641, containing four Lactobacillus and two Bifidobacillus strains) for 3 months did not affect serum ALT, AST, and ALP in patients with primary sclerosing cholangitis [51].”
ResultRetractedRole of the Microbiota and Antibiotics in Primary Sclerosing Cholangitis
Tabibian, J. H., Talwalkar, J. A., & Lindor, K. D. (2013) · BioMed Research International · doi:10.1155/2013/389537 · Cited by 91
“Of note, there have also been a case report and a small randomized trial of probiotics in PSC which yielded conflicting results [69, 70].”
ResultProbiotic as a Novel Treatment Strategy Against Liver Disease
Imani Fooladi, A. A., Hosseini, H. M., Nourani, M. R., Khani, S., & Alavian, S. M. (2013) · Hepatitis Monthly · doi:10.5812/hepatmon.7521 · Cited by 87
“In addition, bilirubin, alkaline phosphatase, gamma glutamyl transpeptidase, aspartate aminotransferase, alanine aminotransferase, prothrombin, albumin, and bile salts levels were not significantly different between the probiotic and placebo groups (79).”
BackgroundCholestatic liver diseases: new targets, new therapies
Santiago, P., Scheinberg, A. R., & Levy, C. (2018) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284818787400 · Cited by 87
Vesterhus, M., & Karlsen, T. H. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01681-z · Cited by 80
Shah, A., Macdonald, G. A., Morrison, M., & Holtmann, G. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000604 · Cited by 82
Probiotics in Inflammatory Bowel Diseases and Associated Conditions
Mack, D. R. (2011) · Nutrients · doi:10.3390/nu3020245 · Cited by 78
Damman, J. L., Rodriguez, E. A., Ali, A. H., Buness, C. W., Cox, K. L., Carey, E. J., & Lindor, K. D. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14540 · Cited by 77
“Vleggaar et al published a randomised placebo-controlled crossover study that showed no difference between patients with IBD and PSC treated with probiotics alone or placebo.(46)”
BackgroundResponders and non-responders to probiotic interventions: How can we improve the odds?
Reid, G., Gaudier, E., Guarner, F., Huffnagle, G. B., Macklaim, J. M., Munoz, A. M., Martini, M., Ringel-Kulka, T., Sartor, B. R., Unal, R. R., et al. (2010) · Gut Microbes · doi:10.4161/gmic.1.3.12013 · Cited by 76
Drug Therapies for Chronic Cholestatic Liver Diseases
Wagner, M., & Fickert, P. (2019) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021059 · Cited by 79
The gut microbial influence on cholestatic liver disease
Kummen, M., & Hov, J. R. (2019) · Liver International · doi:10.1111/liv.14153 · Cited by 74
Yu, L., Liu, Y., Wang, S., Zhang, Q., Zhao, J., Zhang, H., Narbad, A., Tian, F., Zhai, Q., & Chen, W. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2181930 · Cited by 76
The Microbiome in Primary Sclerosing Cholangitis: Current Evidence and Potential Concepts
Hov, J., & Karlsen, T. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1608801 · Cited by 65
Khalesi, S., Johnson, D. W., Campbell, K., Williams, S. L., Fenning, A. S., Saluja, S., & Irwin, C. G. (2017) · European Journal of Nutrition · doi:10.1007/s00394-017-1568-y · Cited by 65
Tabibian, J. H., Ali, A. H., & Lindor, K. D. (2018) · Europe PMC (PubMed Central) · Cited by 65
Sharma, V., Garg, S., & Aġġarwal, S. (2013) · The Permanente Journal · doi:10.7812/tpp/12-144 · Cited by 58
Dean, G., Hanauer, S. B., & Levitsky, J. (2020) · Hepatology · doi:10.1002/hep.31311 · Cited by 53
“PSC-IBD (%) 55 (65) 48 (73) 13 (100) 32 (74)”
BackgroundThe Gut Microbiota: A Novel Player in Autoimmune Hepatitis
Cheng, Z., Yang, L., & Chu, H. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.947382 · Cited by 55
Pande, C., Kumar, A., & Sarin, S. K. (2012) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3283537d61 · Cited by 49
Sivamaruthi, B. S. (2018) · Asian Pacific Journal of Tropical Biomedicine · doi:10.4103/2221-1691.228000 · Cited by 48
“[79] Vleggaar FP, Monkelbaan JF, van Erpecum KJ.”
BackgroundScarpellini, E., Fagoonee, S., Rinninella, E., Rasetti, C., Aquila, I., Larussa, T., Ricci, P., Luzza, F., & Abenavoli, L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082488 · Cited by 43
Role of microbiome in autoimmune liver diseases
Schneider, K. M., Kummen, M., Trivedi, P. J., & Hov, J. R. (2023) · Hepatology · doi:10.1097/hep.0000000000000506 · Cited by 40
“[224] Despite already being used as an over-the-counter medication, there are many fundamental questions that need to be clarified before use in a clinical context.”
BackgroundNovel approaches to intervene gut microbiota in the treatment of chronic liver diseases
Liu, C., Wang, Y., Yang, Y., Zhang, N., Niu, C., Shen, X., & Wu, J. H. (2021) · The FASEB Journal · doi:10.1096/fj.202100939r · Cited by 40
Current evidence on the use of probiotics in liver diseases
Chávez-Tapia, N. C., González-Rodríguez, L., Jeong, M., López-Ramírez, Y., Barbero-Becerra, V. J., Juárez-Hernández, E., Romero-Flores, J. L., Arrese, M. A., Méndez‐Sánchez, N., & Uribe, M. (2015) · Journal of Functional Foods · doi:10.1016/j.jff.2015.05.009 · Cited by 39
Asemi, Z., Aarabi, M. H., Hajijafari, M., Alizadeh, S., Razzaghi, R., Mazoochi, M., & Esmaillzadeh, A. (2017) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_257_16 · Cited by 39
“[43] However, no significant effects of probiotics (Ecologic 641, containing four Lactobacillus and two Bifidobacillus strains) were observed on serum bilirubin, ALP, ALT, AST, GGT, prothrombin, albumin, or bile salts in primary sclerosing cholangitis patients for 3 months.[44] Furthermore, consumption of E.”
BackgroundProbiotics in hepatology: An update
Maslennikov, R. V., Ivashkin, V. T., Efremova, I., Poluektova, E. A., & Shirokova, E. N. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i9.1154 · Cited by 39
Is There a Role for Probiotics in Liver Disease?
Lo, R., Austin, A. S., & Freeman, J. G. (2014) · The Scientific World JOURNAL · doi:10.1155/2014/874768 · Cited by 37
“On the other hand, in patients with primary sclerosing cholangitis, treatment with a probiotics cocktail containing four Lactobacillus and two Bifidobacillus strains did not improve clinical symptoms or liver function tests [56].”
BackgroundTherapy of Primary Sclerosing Cholangitis - Today and Tomorrow
Halilbasic, E., Fuchs, C. D., Hofer, H., Paumgartner, G., & Trauner, M. (2015) · Digestive Diseases · doi:10.1159/000440827 · Cited by 36
The Microbiome in Autoimmune Liver Diseases: Metagenomic and Metabolomic Changes
Zheng, Y., Ran, Y., Zhang, H., Wang, B., & Zhou, L. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.715852 · Cited by 32
Elshaer, A. M., El-Kharashi, O. A., Hamam, G. G., Nabih, E. S., Magdy, Y., & Samad, A. A. A. E. (2019) · Tissue and Cell · doi:10.1016/j.tice.2019.07.010 · Cited by 28
Microbial Players in Primary Sclerosing Cholangitis: Current Evidence and Concepts
Özdirik, B., & Schnabl, B. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.12.005 · Cited by 27
Role of intestinal flora in primary sclerosing cholangitis and its potential therapeutic value
Li, Z.-J., Gou, H.-Z., Zhang, Y., Song, X., & Zhang, L. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i44.6213 · Cited by 27
Microbiota, immunity and the liver
Vaikunthanathan, T., Safinia, N., Lombardi, G., & Lechler, R. I. (2016) · Immunology Letters · doi:10.1016/j.imlet.2016.01.008 · Cited by 24
“reported that the use of a multi-strain probiotic in patients with PSC and inflammatory bowel disease, for three months had no benefit for symptomatic relief of pruritus, fatigue and stool frequency [149].”
BackgroundMedical and endoscopic therapy of primary sclerosing cholangitis
Weismüller, T. J., & Lankisch, T. O. (2011) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2011.10.003 · Cited by 27
Pharmacological interventions for primary sclerosing cholangitis
Saffioti, F., Gurusamy, K. S., Hawkins, N., Toon, C. D., Tsochatzis, E. A., Davidson, B. R., & Thorburn, D. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011343.pub2 · Cited by 28
Al-Shakhshir, S., Quraishi, M. N., Mullish, B. H., Patel, A. M., Vince, A., Rowe, A. L., Homer, V., Jackson, N., Gyimah, D., Shabir, S., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-095392 · Cited by 20
“31 A recent pilot study demonstrated that gut micro-biome composition in PSC can be modulated using FMT, a process by which minimally manipulated stool from healthy screened donors is processed in an approved facility and administered to patients.”
Systematic review: microbial manipulation as therapy for primary sclerosing cholangitis
Bogatic, D., Bryant, R. V., Lynch, K. D., & Costello, S. P. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17251 · Cited by 19
The gut-liver axis in hepatobiliary diseases
Ichikawa, M., Okada, H., Nakamoto, N., Taniki, N., Chu, P., & Kanai∥, T. (2024) · Inflammation and Regeneration · doi:10.1186/s41232-023-00315-0 · Cited by 19
“Conversely, certain reports have indicated that the effect of probiotics on hepatic encephalopathy was limited [139] and that probiotics for PSC failed to show efficacy [105].”
BackgroundTreatment options for primary sclerosing cholangitis
Sinakos, E., & Lindor, K. D. (2010) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.10.33 · Cited by 20
Successful Treatment of Primary Sclerosing Cholangitis with a Steroid and a Probiotic
Shimizu, M., Iwasaki, H., Mase, S., & Yachie, A. (2012) · Case Reports in Gastroenterology · doi:10.1159/000338834 · Cited by 19
Zhou, H., Huang, Y., Chen, C., Song, M., & Hylemon, P. B. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100120 · Cited by 19
Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease
Kim, Y. S., Hurley, E., Park, Y., & Ko, S. (2023) · Intestinal Research · doi:10.5217/ir.2023.00039 · Cited by 17
“99) were observed.(82) One patient in placebo group experienced IBD flare and improved by steroid treatment.”
BackgroundFu, Y., Li, J., Zhu, Y., Chen, C., Liu, J., Gu, S., Zheng, Y., & Li, Y. (2023) · BMC Medical Genomics · doi:10.1186/s12920-023-01670-0 · Cited by 19
“However, a randomized, placebo-controlled study of probiotics in patients with PSC did not show any benefits in relieving PSC symptoms, indicating that probiotics alone may not be effective in treating PSC [48].”
BackgroundGut Microbiome and Bile Acid Interactions
Wu, N., Bayatpour, S., Hylemon, P. B., Aseem, S. O., Brindley, P. J., & Zhou, H. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.11.004 · Cited by 17
Probiotics in Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Cirrhosis
Qamar, A. (2015) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000347 · Cited by 18
“Mittal et al41 Primary prevention of hepatic encephalopathy 4 groups compared (1) No treatment (2) Lactulose (3) Probiotics (4) L-ornithine L-aspartate 160 3mo Hepatic encephalopathy incidence Group 1: 10%”
MethodImpact of Gut Microbiome on Gut Permeability in Liver and Gut Diseases
Saha, P., & Hartmann, P. (2025) · Microorganisms · doi:10.3390/microorganisms13061188 · Cited by 16
“Vleggaar et al. conducted an RCT in 14 adult patients with PSC–IBD using probiotics comprising six strains ( Lactobacillus acidophilus , Lactobacillus casei , Lactobacillus salivarius , Lactococcus lactis , Bifidobacterium bifidum , and Bifidobacterium lactis ) for 3 months [181].”
Gut microbiome in liver pathophysiology and cholestatic liver disease
Yan, S., & Yin, X. (2021) · Liver Research · doi:10.1016/j.livres.2021.08.001 · Cited by 19
Liver transplant in primary sclerosing cholangitis: Current trends and future directions
Shah, Y. R., Nombera-Aznaran, N., Guevara-Lazo, D., Martinez, E. C., Tiwari, A., Kanumilli, S., Shah, P. C., Pinnam, B. S. M., Ali, H., & Dahiya, D. S. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i8.939 · Cited by 19
Microbiome and gut-liver interactions: From mechanisms to therapies
Anis, M. A., Shahid, Y., Majeed, A. A., & Abid, S. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i40.111409 · Cited by 18
“Results showed no significant improvement in symptoms, liver biochemistry, or fibrosis markers with probiotics, highlighting inconsistent clinical outcomes[95].”
Intestinal homeostasis in autoimmune liver diseases
Liu, Q., He, W., Tang, R., & Ma, X. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002291 · Cited by 13
Gut Microbiota in Primary Sclerosing Cholangitis: From Prognostic Role to Therapeutic Implications
Maccauro, V., Fianchi, F., Gasbarrini, A., & Ponziani, F. R. (2024) · Digestive Diseases · doi:10.1159/000538493 · Cited by 12
“…investigating a probiotic containing four Lactobacillus and two Bi fi - dobacterium species in 14 patients with PSC-IBD, nor changes in pruritus, fatigue, and stool frequency were noted in the two groups, neither signi fi cant differences were observed in liver function and cholestasis indices [59].”
Therapeutic manipulation of the microbiome in liver disease
Parthasarathy, G., Malhi, H., & Bajaj, J. S. (2024) · Hepatology · doi:10.1097/hep.0000000000000987 · Cited by 15
The Role of the Gastrointestinal Microbiome in Liver Disease
Shalaby, N., Samocha‐Bonet, D., Kaakoush, N. O., & Danta, M. (2023) · Pathogens · doi:10.3390/pathogens12091087 · Cited by 11
“However, the same has not been found in primary sclerosing cholangitis, where a small pilot trial found no significant changes to liver markers after three months [130].”
Probiotics in Pediatric Liver Disease
Miloh, T. (2015) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000365 · Cited by 11
Zhang, X., Wan, L., Zheng, Y., & Ai, Y. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl27747 · Cited by 10
Probiotics for the Treatment of Liver Disease
Punzalan, C., & Qamar, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804024-9.00040-9 · Cited by 10
Functional roles of gut bacteria imbalance in cholangiopathies
Sato, K., Meng, F., Fava, G., Glaser, S. S., & Alpini, G. D. (2018) · Liver Research · doi:10.1016/j.livres.2018.11.001 · Cited by 9
An overview of recent treatment options for primary sclerosing cholangitis
Mousavere, I., Kalampokis, G., Fousekis, F., Karayiannis, P., Baltayiannis, G., & Christodoulou, D. (2023) · Annals of Gastroenterology · doi:10.20524/aog.2023.0834 · Cited by 9
“Probiotic supplementation therapy was evaluated in a small crossover randomized controlled trial (n=14, 3 months) involving PSC patients treated with a combination of 4 Lactobacillus and 2 Bifidobacillus strains [89].”
MethodZhao, J., Yue, P., Mi, N., Li, M., Fu, W., Zhang, X., Gao, L., Bai, M., Tian, L., Jiang, N., et al. (2024) · Medical Review · doi:10.1515/mr-2024-0029 · Cited by 11
Chang, G., Sun, J., Li, J., & Li, T. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102361 · Cited by 7
New agents for immunosuppression
Jefremow, A., & Neurath, M. F. (2021) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2021.101763 · Cited by 7
Autoimmune liver disease and the enteric microbiome
Glassner, K. L., Quigley, E. M. M., Franco, L., & Victor, D. W. (2018) · AIMS Microbiology · doi:10.3934/microbiol.2018.2.334 · Cited by 6
“Fourteen patients with PSC and IBD who were treated with a probiotic cocktail containing lactobacillus and bifidobacterium strains did not show any improvement in clinical symptoms or laboratory parameters [37].”
BackgroundSelected Aspects of the Intricate Background of Immune-Related Cholangiopathies—A Critical Overview
Kasztelan‐Szczerbińska, B., Rycyk, A., Szczerbińska, A., & Cichoż‐Lach, H. (2023) · Nutrients · doi:10.3390/nu15030760 · Cited by 6
Effects of Probiotics on Liver Diseases: Current In Vitro and In Vivo Studies
Sadri, M., Shafaghat, Z., Roozbehani, M., Hoseinzadeh, A., Mohammadi, F., Arab, F. L., Minaeian, S., Fard, S. R., & Faraji, F. (2024) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-024-10431-z · Cited by 6
Losa, M., Schwarzfischer, M., Emmenegger, M., Spalinger, M. R., Rogler, G., & Scharl, M. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168042 · Cited by 4
“…Lactobacillus and two Bifidobacillus strains did not show any changes in pruritus, fatigue, stool frequency, or biochemical profiles (i.e., alkaline phosphatase (ALP), gamma-glutamyl transferase, liver transaminases, bile salts, or albumin) during either placebo or probiotic administration [219].”
Taghizadeh, M., Alizadeh, S., & Asemi, Z. (2015) · Women’s Health Bulletin · doi:10.17795/whb-27195 · Cited by 4
“In addition, no significant effects were observed in patients with primary sclerosing cholangitis (PSC) on serum ALT, AST and ALP concentrations after consumption of probiotics containing four Lactobacillus and two Bifidobacillus strains after 3 months (33).”
BackgroundPark, K., Kim, J. Y., Roh, S. W., Savaliya, B., Turner, C. A., Pirius, N., LaRusso, N. F., Song, K., & O’Hara, S. P. (2026) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2026.101789 · Cited by 4
Мікробіота та захворювання гепатобіліарної системи: нові можливості в лікуванні дітей раннього віку
Shadrin, O. H., & Чернега, Н. Ф. (2020) · CHILD`S HEALTH · doi:10.22141/2224-0551.5.65.2015.74877 · Cited by 3
Novel preclinical developments of the primary sclerosing cholangitis treatment landscape
Sohal, A., & Kowdley, K. V. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2330738 · Cited by 4
“Probiotics have also been evaluated as potential therapy for the treatment of PSC but failed to show clinical benefit in a small study [99].”
BackgroundReview of pharmacotherapeutic treatments for primary sclerosing cholangitis
Zhang, C., Hussaini, T., & Yoshida, E. M. (2019) · Canadian Liver Journal · doi:10.3138/canlivj-2018-0016 · Cited by 3
Primary and Secondary Sclerosing Cholangitis
Bowlus, C. L., Assis, D. N., & Goldberg, D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-37591-7.00043-4 · Cited by 3
Pruritus in Primary Sclerosing Cholangitis: New Insights into Cause and Treatment
Swain, M. G. (2016) · Springer eBooks · doi:10.1007/978-3-319-40908-5_10 · Cited by 3
Emerging Targets for the Treatment of Primary Sclerosing Cholangitis
Tatscher, E., Mady, S., & Fickert, P. (2025) · Seminars in Liver Disease · doi:10.1055/a-2601-9426 · Cited by 1
Future Treatment Options for Managing Primary Sclerosing Cholangitis and Cholestatic Pruritus
Das, T. S., & Vuppalanchi, R. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.06.010 · Cited by 1
Mammadov, R. A., Roest, H. P., van der Laan, L. J. W., & Peppelenbosch, M. P. (2025) · Journal of Nutrition · doi:10.1016/j.tjnut.2025.10.041 · Cited by 1
“Probiotic strains like Lactobacillus and Bifidobacterium have been specifically studied in PSC contexts, with some small trials reporting reductions in alkaline phosphatase and improvements in gut barrier function by decreasing intestinal permeability [84, 131,143].”
Microbiome-immune interactions in autoimmune liver diseases
Kiseleva, Y. V., Maslennikov, R. V., Poluektova, E. A., Zolnikova, O., Sigidaev, A. S., Zharikov, Y. O., Shirokova, E. N., & Ivashkin, V. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i12.115853 · Cited by 1
Ali, A. H., Carey, E. J., & Lindor, K. D. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.908701 · Cited by 1
“Bifidobacillus on the symptoms and liver chemistries in PSC patients [72].”
BackgroundMethodPrimary Sclerosing Cholangitis
Chandra, N., Cullen, S. N., & Chapman, R. W. (2010) · Wiley eBooks · doi:10.1002/9781444314403.ch34 · Cited by 1
Rigopoulou, E. I., Koutsoumpas, A. L., & Bogdanos, D. P. (2022) · Springer eBooks · doi:10.1007/978-981-19-1946-6_6 · Cited by 1
Абатуров, А. Е., & Babуch, V. L. (2024) · CHILD`S HEALTH · doi:10.22141/2224-0551.18.8.2023.1657 · Cited by 1
Navigating the liver landscape: upcoming pharmacotherapies for primary sclerosing cholangitis
Pham, H. N., Pham, L., & Sato, K. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2362263 · Cited by 1
“A pilot study administered probiotics (Ecologic 641) to 14 patients with PSC and concurrent IBD for 3 months, but this study could not identify any clinical improvement, such as lowered ALP levels compared to placebo [52].”
MethodPharmacological treatments for primary sclerosing cholangitis: a network meta-analysis
Gurusamy, K. S., Saffioti, F., Toon, C. D., Tsochatzis, E. A., Davidson, B. R., & Thorburn, D. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011343 · Cited by 1
Pierwotne stwardniające zapalenia przewodów żółciowych – znaczenie czynników żywieniowych
Wróblewska, E., Piotr, T., & Okręglicka, K. (2014) · Family Medicine & Primary Care Review
16 Use of Complementary and Alternative Therapies in Hepatic Disorders
Dadabhai, A. S. (2015) · CRC Press eBooks · doi:10.1201/9781315100913-17
Metadata
- Authors
- Vleggaar, F. P., Monkelbaan, J. F., & van Erpecum, K. J.
- Affiliations
- University Medical Center Utrecht (NL)
- Corresponding author
- Vleggaar, Frank P.
- Venue
- European Journal of Gastroenterology & Hepatology
- Published
- 2008-07
- Volume
- 20
- Issue
- 7
- Pages
- 688-692
- ISSN
- 0954-691X (ISSN-L)
- OpenAlex
- W2062111585
- Cited by
- 110
- References
- 20
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 10 · 2023: 9 · 2022: 9 · 2021: 10 · 2020: 6 · 2019: 6 · 2018: 8 · 2017: 9 · 2016: 2 · 2015: 9 · 2014: 6 · 2013: 3 · 2012: 4
- FWCI
- 1.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Gastroenterology & Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Keywords
- probiotics, primary sclerosing cholangitis, inflammatory bowel disease, Lactobacillus, Bifidobacterium, liver function tests, pruritus, fatigue, bile acid metabolism, gut-liver axis
- MeSH terms
- Adult, Aged, Alkaline Phosphatase, Bifidobacterium, Bilirubin, Epidemiologic Methods, Fatigue, Female, Humans, Lactobacillus, Liver, Male, Middle Aged, Pruritus, Cholangitis, Sclerosing, Biomarkers, Treatment Outcome, Probiotics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.